Vir Biotechnology Inc
Закрыт
СекторЗдравоохранение
10 -1.57
Обзор
Изменение цены акций
24 ч
Мин.
9.99
Макс.
10.37
Доход | -83M -126M |
|---|---|
Продажи | -64M -29K |
Прибыль на акцию | -0.85 |
Рентабельность продаж | 433,431.034 |
Сотрудники | 367 |
EBITDA | -83M -123M |
Рекомендации | Активная покупка |
|---|---|
Прогноз на 12 месяцев | +110.93% upside |
Следующий отчет о доходах | 5 авг. 2026 г. |
|---|
Рыночная капитализация | -27M 1.6B |
|---|---|
Предыдущая цена открытия | 11.57 |
Предыдущая цена закрытия | 10 |
Новостные настроения
By Acuity
34%
66%
87 / 342 Рейтинг в Healthcare
Vir Biotechnology Inc График
Прошлые результаты не являются надежным индикатором будущих результатов.
О компании Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.